CAMBRIDGE, Mass., April 6,
2022 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC), a precision therapy company focused on genomically
defined cancers, rare diseases and cancer immunotherapy, today
announced that, effective on April 1,
2022, the Compensation Committee of Blueprint Medicines'
Board of Directors granted non-qualified stock options to purchase
an aggregate of 13,337 shares of its common stock and an aggregate
of 6,665 restricted stock units (RSUs) to thirteen new employees
under Blueprint Medicines' 2020 Inducement Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ
Listing Rules.
The options have an exercise price of $65.40 per share, which is equal to the closing
price of Blueprint Medicines' common stock on April 1, 2022. Each option will vest as to 25% of
the shares underlying such option on the first anniversary of the
grant date and as to an additional 1/48th of the shares underlying
the option monthly thereafter, in each case, subject to each
such employee's continued employment on each vesting date. Each RSU
will vest as to 25% of the shares underlying the RSU award on the
first anniversary of the grant date and as to an additional 25% of
the shares underlying the RSU award annually thereafter, subject to
each such employee's continued employment on each vesting date. The
options and RSUs are subject to the terms and conditions of
Blueprint Medicines' 2020 Inducement Plan, and the terms and
conditions of the stock option and RSU agreement covering the
grant.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities, to
rapidly and reproducibly translate science into a broad pipeline of
precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on
Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301518721.html
SOURCE Blueprint Medicines Corporation